As of June 30, 2026, ABL Texcell Diagnostics carries a market capitalization of 44.70M, placing it among publicly traded companies globally. Its enterprise value stands at 45.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 44.70M |
| Enterprise Value | 45.66M |
ABL Texcell Diagnostics's next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2026, ABL Texcell Diagnostics has 16.08M shares outstanding.
| Shares Outstanding | 16.08M |
These figures are as of June 30, 2026.
| PB Ratio | 6.30 |
| P/TBV Ratio | 11.65 |
As of June 30, 2026, ABL Texcell Diagnostics maintains a current ratio of 2.26, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.26 |
| Quick Ratio | 0.21 |
| Debt / Equity | 25.48 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 21.00 |
As of the close on November 17, 2026, ABL Texcell Diagnostics's stock has declined approximately 17.24% over the past 52 weeks. The 50-day moving average sits at 2.38, while the 200-day moving average is 2.74.
| 52-Week Price Change | -17.24% |
| 50-Day Moving Average | 2.38 |
| 200-Day Moving Average | 2.74 |
As of June 30, 2026, ABL Texcell Diagnostics holds 853,726.00 in cash and equivalents against 1.81M in total debt, resulting in a net debt position of 1.12M. Total book value stands at 7.10M, with working capital of 5.10M providing operational flexibility.
| Cash & Cash Equivalents | 853,726.00 |
| Total Debt | 1.81M |
| Net Debt | 1.12M |
| Equity (Book Value) | 7.10M |
| Book Value Per Share | 0.44 |
| Working Capital | 5.10M |
ABL Texcell Diagnostics's most recent stock split took place on May 18, 2022 with a 1:8 split ratio.
| Last Split Date | 5/18/2022 |
| Split Ratio | 1:8 |
Already premium?